How to assess an inherited go-to-market strategy

When you inherit a go-to-market strategy, you are not inheriting a clean plan. You are inheriting past decisions shaped by different market conditions, priorities, and assumptions. The first step is not to audit performance, but to assess strategic fit. Map every revenue-impacting asset, classify each by its intended role, and apply a leverage test to determine whether it reduces cost, increases speed, or expands reach. Only then can you confidently decide what to double down on, stabilise, or sunset.

The need-to-know:

  1. Audit fit before performance: Performance metrics mislead without context; strategic fit reveals whether you would build the asset again today

  2. Classify by role, not sentiment: Every GTM asset must be a Core Engine, Strategic Bet, or Legacy Drag—anything undefined defaults to drag

  3. Apply the leverage test ruthlessly: If an asset does not reduce cost, increase speed, or expand reach—and compound over time—it is activity, not leverage.

Let’s go a little further

Walking into a new go-to-market leadership role feels deceptively simple. You open the CRM. You review campaigns. You scan the partner list. It all looks active.

Activity is not strategy.

What you have inherited is not a coherent growth system. It is a portfolio of decisions frozen in time. Some were right for a different stage. Some solved short-term pressure. Some were politically convenient.

Your responsibility is not to defend them. It is to assess whether they still fit.

Most leaders start with performance metrics. Revenue. Pipeline. Conversion rates. These matter, but they are lagging indicators. They do not tell you whether the asset aligns with your current ideal customer profile, buying motion, sales capacity, or market timing.

Instead, begin with a harder question:

If we were starting from zero today, would we build this again?

That question strips away history and politics.

To answer it properly, map the entire go-to-market portfolio. Direct sales motions. Marketing channels. Partnerships. Product-led growth paths. Operational enablers. If it touches revenue, it goes on the list.

Then classify each asset by role:

  • Core Engine — predictable, scalable, funded with confidence.

  • Strategic Bet — experimental, time-bound, learning-focused.

  • Legacy Drag — unclear ownership, fuzzy outcomes, emotional attachment.

Notice there is no “working fine” category. Undefined equals drag.

From there, apply the leverage test.

  1. Does this asset reduce cost, increase speed, or expand reach?

  2. Does it compound over time?

  3. Does it survive without heroics?

Leverage simplifies execution and strengthens with repetition. Low-leverage assets demand constant justification.

Partnership portfolios are especially vulnerable here. Many exist in permanent “strategic bet” limbo, without defined contribution to demand, acceleration, expansion, or cost efficiency. A partner without a clear go-to-market role is just a logo.

Once fit, role, and leverage are clear, the actions follow naturally:

  1. Double down,

  2. Stabilise, or

  3. Sunset

Sunsetting is not failure. It is focus.

The goal is not to create a perfect map. It is to create confidence. Confidence that resources match strategy. Confidence that momentum is protected. Confidence that your team knows what matters now.

In your first 90 days, clarity builds trust faster than charisma.

Assess first. Then act.

Question for you

What part of this approach has stayed with you? Let me know.

 

When you're ready, here’s one way I can help you:

The Partnership Lab: A 6-week experience for founders, CEOs, and GTM leaders who are done with slow growth and stalled conversations. Learn to rapidly qualify and prioritise high-value partners, install a system that turns conversations into contracts and capture outsized returns from partnerships that scale. Apply to join the next cohort today!

Looking for something different? Send me an email.

 
Previous
Previous

How are pharmacists reshaping patient care? Leadership lessons from the healthcare frontline

Next
Next

CEO Doug Taylor on leadership, education and ending disadvantage